| US 7,501,487 B1 | ||
| Retinoid receptor compositions and methods | ||
| David J. Mangelsdorf, San Diego, Calif. (US); and Ronald M. Evans, La Jolla, Calif. (US) | ||
| Assigned to The Salk Institute for Biological Studies, La Jolla, Calif. (US) | ||
| Filed on Jun. 05, 1995, as Appl. No. 8/467,543. | ||
| Application 08/467543 is a continuation of application No. 08/336408, filed on Nov. 08, 1994, granted, now 5,723,329. | ||
| Application 08/336408 is a continuation of application No. 07/933453, filed on Aug. 21, 1992, abandoned. | ||
| Application 07/933453 is a continuation of application No. 07/478071, filed on Feb. 09, 1990, abandoned. | ||
| Application 07/478071 is a continuation of application No. PCT/US91/00399, filed on Jan. 22, 1991. | ||
| Int. Cl. A07K 14/00 (2006.01) | ||
| U.S. Cl. 530—350 | 6 Claims |
| 1. A purified retinoid receptor characterized by:
(1) being responsive to the presence of retinoid ligand(s) to regulate the transcription of associated gene(s);
(2) being a member of the steroid/thyroid hormone superfamily of receptors having an N-terminal domain, a DNA binding domain
and a C-terminal domain, wherein:
(i) said N-terminal domain has at least 36% amino acid identity with amino acid residues 1-140 of Sequence ID No. 4; and
(ii) said DNA binding domain has about 66 amino acids with 9 Cys residues, and has:
(a) at least 92% amino acid identity with the DNA binding domain of mRXR-alpha defined by residues 140-205 of Sequence ID
No. 4,
(b) less than about 65% amino acid identity with the DNA binding domain of hRAR-alpha,
(c) less than about 55% amino acid identity with the DNA binding domain of hTR-beta, and
(d) less than about 55% amino acid identity with the DNA binding domain of hGR;
(3) not including the amino acid sequence set forth in Sequence ID No. 8.
|